This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Aydin, K. Articles by Gucuyener, K. Search for Related Content PubMed PubMed Citation Articles by Aydin, K. Articles by Gucuyener, K. Social Bookmarking                         What's this?

Serum Insulin, Leptin, and Neuropeptide Y Levels in Epileptic Children Treated With Valproate

Department of Pediatric Neurology, Selcuk University Meram Medical Medical Faculty, Konya, Turkey, kursadaydin{at}hotmail.com

Ayse Serdaroglu, MD

Department of Pediatric Neurology, Gazi University Medical Faculty, Ankara, Turkey

Cetin Okuyaz, MD

Department of Pediatric Neurology, Mersin University Medical Faculty, Mersin, Turkey

Aysun Bideci, MD

Department of Pediatric Endocrinology, Gazi University Medical Faculty, Ankara, Turkey

Kivilcim Gucuyener, MD

Department of Pediatric Neurology, Gazi University Medical Faculty, Ankara, Turkey

Weight gain is a common side effect of valproate treatment. The potential mechanisms of valproate-associated weight gain are not yet clear. Decreased blood glucose level, impairment of ß-oxidation of fatty acids, and increased insulin levels are some of the possible mechanisms. The aim of the present study is to evaluate the role of insulin, leptin, and neuropeptide Y in valproate-related weight gain in epileptic children. In 20 epileptic children treated with valproate before treatment and after a follow-up period of 3 and 6 months, body mass index and fasting insulin glucose ratio were calculated and serum glucose, insulin, cortisol, leptin, and neuropeptide Y levels were measured. At the end of 3 months, the mean body mass index values and the mean serum insulin, fasting insulin glucose ratio, and neuropeptide Y levels increased, whereas the serum glucose levels decreased. After 6 months of treatment, the mean serum cortisol and leptin levels were high, in addition to the body mass index, neuropeptide Y, and fasting insulin glucose ratio. These results suggest that weight gain during valproate treatment might be related to low glucose and high insulin, cortisol, leptin, and neuropeptide Y levels. (J Child Neurol 2005;20:848—851).

Journal of Child Neurology, Vol. 20, No. 10, 848-851 (2005)
DOI: 10.1177/08830738050200101501


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				Z. S. Daniels, T. G. Nick, C. Liu, A. Cassedy, and T. A. Glauser Obesity is a common comorbidity for pediatric patients with untreated, newly diagnosed epilepsy Neurology, September 1, 2009; 73(9): 658 - 664. [Abstract] [Full Text] [PDF]

				S. Grosso, R. Mostardini, B. Piccini, and P. Balestri Body Mass Index and Serum Lipid Changes During Treatment with Valproic Acid in Children with Epilepsy Ann. Pharmacother., January 1, 2009; 43(1): 45 - 50. [Abstract] [Full Text] [PDF]